Acrivon Therapeutics (ACRV) Competitors

Acrivon Therapeutics (NASDAQ:ACRV) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Which has better valuation & earnings, ACRV or TKNO?

Alpha Teknova has higher revenue and earnings than Acrivon Therapeutics. Alpha Teknova is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$60.39M	-$2.44	-0.57
Alpha Teknova	$37.75M	6.38	-$36.78M	-$0.59	-7.64

Which has more volatility & risk, ACRV or TKNO?

Acrivon Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Does the media prefer ACRV or TKNO?

In the previous week, Acrivon Therapeutics had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.73 beat Acrivon Therapeutics' score of 0.00 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Teknova	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do institutionals and insiders believe in ACRV or TKNO?

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 15.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts rate ACRV or TKNO?

Acrivon Therapeutics currently has a consensus target price of $23.17, indicating a potential upside of 1,566.67%. Alpha Teknova has a consensus target price of $8.50, indicating a potential upside of 88.47%. Given Acrivon Therapeutics' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alpha Teknova	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ACRV or TKNO more profitable?

Acrivon Therapeutics has a net margin of 0.00% compared to Alpha Teknova's net margin of -87.17%. Alpha Teknova's return on equity of -35.30% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-47.95%	-43.73%
Alpha Teknova	-87.17%	-35.30%	-24.52%

Does the MarketBeat Community prefer ACRV or TKNO?

Acrivon Therapeutics received 28 more outperform votes than Alpha Teknova when rated by MarketBeat users. Likewise, 97.37% of users gave Acrivon Therapeutics an outperform vote while only 39.13% of users gave Alpha Teknova an outperform vote.

Company	Underperform	Outperform
Acrivon Therapeutics	Outperform Votes 37 97.37%	Underperform Votes 1 2.63%
Alpha Teknova	Outperform Votes 9 39.13%	Underperform Votes 14 60.87%

Summary

Acrivon Therapeutics beats Alpha Teknova on 9 of the 16 factors compared between the two stocks.